WHO Grade III Ependymal Neoplasm

A WHO grade III ependymal neoplasm—often called anaplastic ependymoma—is a fast-growing tumor that starts from ependymal cells, the cells that line the fluid-filled spaces of the brain and the central canal of the spinal cord. Under the microscope, these tumors look very “busy”: the cells are packed tightly, divide quickly, and may show signs of abnormal blood vessels and small dead areas (necrosis). These features tell doctors that the tumor is more aggressive than lower-grade (grade 1–2) ependymomas. Today’s WHO system (2021 “CNS5”) classifies ependymomas mainly by where they arise (supratentorial brain, posterior fossa, or spine) and by molecular features (certain gene fusions or amplifications). The older label “anaplastic ependymoma (grade III)” is still used in many reports to indicate high-grade behavior within those modern types. PMC+1

A WHO grade III ependymal neoplasm—often called anaplastic ependymoma—is a fast-growing primary tumor that starts from ependymal cells lining the fluid-filled spaces inside the brain and spinal cord. “Grade III” means the tumor cells look more abnormal and grow faster than lower-grade ependymomas. Today, doctors also look at where in the brain or spine the tumor is and its molecular features (such as ZFTA-fusion, YAP1-fusion, and posterior fossa groups A/B) because these factors often predict outcome better than grade alone. Standard care usually combines maximal safe surgery and focused radiation to the tumor bed; chemotherapy has a limited, selective role and is more common in trials or recurrence. Prognosis depends on complete removal, tumor location, spread in spinal fluid, and the tumor’s molecular subtype. Cancer.gov+2PMC+2

---

Other names

You may also see: anaplastic ependymoma, WHO grade III ependymoma, high-grade ependymoma, malignant ependymoma. These phrases all point to the same concept: an ependymoma with aggressive (high-grade) microscopic features. In 2021 WHO CNS5, grading is applied within each location/molecular type, and the term “anaplastic” is less emphasized—but many pathologists still use it to communicate high-grade features clearly. PMC

---

Types

Modern classification combines anatomic site and molecular profile. Grade III histology can be seen in several of these categories:

1. Supratentorial (cerebral) ependymoma, ZFTA fusion–positive: Often aggressive; previously called “RELA fusion–positive.” ZFTA is the newer, more accurate label. PMC+1

2. Supratentorial ependymoma, YAP1 fusion–positive: Less common; defined by a different gene fusion. PMC+1

3. Posterior fossa ependymoma, Group A (PFA) and Group B (PFB): Pediatric-skewed (PFA) vs more adolescent/adult (PFB) epigenetic groups; grading occurs within these groups. PMC

4. Spinal ependymoma (including MYCN-amplified subtype): Spinal tumors are more common in adults; a MYCN-amplified subset behaves aggressively. American Journal of Neuroradiology+1

---

Causes

For brain tumors, a single “cause” is rarely known. The items below summarize biologic drivers and risk associations linked to grade-III behavior or to ependymoma formation in general. Think of them as factors associated with how and why these tumors arise or behave, not as proven one-to-one causes in every patient.

1. ZFTA gene fusion (supratentorial): This fusion reprograms tumor cells and is tightly linked to supratentorial ependymoma; many such tumors show high-grade features. PMC+1

2. YAP1 gene fusion (supratentorial): A distinct oncogenic driver defining another supratentorial subtype. PMC+1

3. MYCN amplification (spinal): Extra copies of MYCN correlate with aggressive biology in spinal ependymoma. American Journal of Neuroradiology+1

4. Posterior fossa epigenetic program (PFA): PFA tumors show a unique epigenetic state (including global H3K27me3 loss via EZHIP overexpression) that relates to behavior and prognosis. Lippincott Journals

5. Chromosome 22q/NF2 alterations (especially spinal): NF2 pathway changes are frequent in spinal ependymomas and contribute to tumorigenesis. PMC

6. 1q gain and other copy-number changes: Certain chromosomal imbalances (e.g., gain of 1q) associate with poorer outcomes. PMC

7. High proliferative index (Ki-67): A high Ki-67 reflects rapid cell division, a hallmark of grade-III histology. Pathology Department

8. Microvascular proliferation and necrosis: These microscopic features are part of the definition of anaplasia and signal aggressive growth. Pathology Department

9. Molecular signaling shifts (e.g., NF-κB in ZFTA-activated tumors): Downstream pathway activation supports growth and survival. PMC

10. Developmental cell-of-origin programs: Ependymomas may arise from progenitors with region-specific developmental signals. PMC

11. Posterior fossa tumor microenvironment: Local factors (hypoxia, niche signals) are hypothesized contributors to PFA biology. PMC

12. Prior cranial or spinal irradiation (rare, latency-linked): A recognized but uncommon risk for radiation-induced gliomas/ependymomas. (Discussed in guidelines as a clinical consideration.) PMC

13. Age-related biology: Children more often have supratentorial fusions or PFA patterns; adults more often have spinal disease. Biology tracks with age group. Frontiers+1

14. Sex distribution within subgroups: Some subtypes (e.g., PFA) skew by sex/age, reflecting underlying biology rather than behavior alone. Frontiers

15. Methylation class: Genome-wide methylation signatures define subgroups and correlate with outcome. PMC

16. H3K27me3 immunoprofile: Loss of H3K27me3 staining supports PFA biology, associated with risk in children. Lippincott Journals

17. L1CAM expression (surrogate of ZFTA-activation): An IHC marker that tracks with the ZFTA-driven subtype and more aggressive behavior. Lippincott Journals

18. Tumor genetic heterogeneity: Mixtures of clones can drive progression to higher grade within a tumor. PMC

19. Surgical accessibility (indirect factor): Deep or adherent tumors that cannot be fully removed tend to recur sooner; this is a clinical risk factor even though it is not a biological mutation. PMC

20. Histologic anaplasia itself: The presence of anaplastic features predicts worse progression-free survival. PMC

---

Symptoms

Symptoms vary with location: brain vs. spine, and exact site within those regions.

1. Headache – Often worse in the morning or with straining. Pressure rises when fluid pathways are blocked. Mayo Clinic

2. Nausea and vomiting – Another sign of raised pressure inside the skull. Mayo Clinic

3. Blurred or double vision – From swelling of the optic nerves (papilledema) or brainstem/cranial nerve involvement. Cancer.gov

4. Seizures – More common in supratentorial (cerebral) tumors. Frontiers+1

5. Weakness on one side of the body – A focal neurological deficit if motor pathways are affected. NewYork-Presbyterian

6. Numbness or tingling – Sensory pathway involvement in brain or spine. NewYork-Presbyterian

7. Poor balance or clumsiness – Cerebellar/posterior fossa tumors often cause ataxia and gait problems. Frontiers

8. Facial weakness or swallowing trouble – Cranial nerve symptoms with posterior fossa lesions. NewYork-Presbyterian

9. Sleepiness or behavior change – Pressure effects, hydrocephalus, or location-specific brain dysfunction. Cancer.gov

10. Back pain – Typical of spinal ependymoma; may worsen with cough/strain. My Active Health

11. Shooting leg pain (radiculopathy) – From nerve root compression by a spinal tumor. My Active Health

12. Leg weakness or walking difficulty – Spinal cord involvement affecting motor tracts. My Active Health

13. Numbness “band” around the chest/abdomen – A spinal cord “sensory level.” My Active Health

14. Bowel or bladder problems – Late warning signs in spinal disease. My Active Health

15. In infants and toddlers: irritability, enlarged head, delayed milestones – From hydrocephalus or posterior fossa lesions. Cancer.gov

---

Diagnostic tests

In practice, doctors combine exam, imaging, surgery/biopsy, and lab/pathology to make a precise diagnosis and stage the disease.

A) Physical examination

1. General neurological exam – Checks alertness, orientation, strength, sensation, reflexes, and coordination; finds focal deficits that suggest where the tumor is. NewYork-Presbyterian

2. Cranial nerve exam – Looks for facial weakness, swallowing or eye movement problems typical of posterior fossa/brainstem involvement. NewYork-Presbyterian

3. Funduscopic exam (looking at the optic nerve) – Detects papilledema (optic disc swelling), a clue to raised intracranial pressure from obstructed CSF flow. Cancer.gov

4. Gait and coordination testing – Bedside checks for balance and limb coordination that point toward cerebellar disease. Frontiers

B) Manual bedside tests

5. Finger-to-nose and heel-to-shin – Simple coordination tasks; inaccuracy suggests cerebellar pathway involvement. Frontiers

6. Tandem gait (heel-to-toe walk) – Stresses balance; instability supports posterior fossa/cerebellar dysfunction. Frontiers

7. Romberg test – Standing with feet together and eyes closed; sway suggests sensory or cerebellar issues. Frontiers

8. Straight-leg raise / Lhermitte’s sign (spine) – Reproduces radicular pain or electric-shock sensation with neck flexion; supports spinal cord/root involvement. My Active Health

C) Laboratory & pathological tests

9. Surgical biopsy or resection for histology – The gold standard. Grade-III tumors show high cellularity, brisk mitoses, microvascular proliferation, and necrosis; classic ependymal rosettes/perivascular pseudorosettes may be seen. Pathology Department

10. Immunohistochemistry (GFAP, EMA “dot-like”/membranous) – Supports ependymal differentiation. Pathology Department

11. Ki-67 labeling index – Measures how fast cells divide; a higher index supports high-grade behavior. Pathology Department

12. L1CAM IHC (surrogate for ZFTA activation) – Helps flag the ZFTA-fusion supratentorial subtype. Lippincott Journals

13. H3K27me3 IHC – Distinguishes posterior fossa Group A (loss) from Group B (retained), aiding risk grouping. Lippincott Journals

14. Molecular testing (RNA/DNA) – Detects ZFTA or YAP1 fusions, MYCN amplification, and other copy-number changes; methylation profiling can classify ambiguous cases. PMC+1

D) Electrodiagnostic tests

15. EEG – Used if seizures are present; maps seizure tendency in supratentorial disease. (Adjunct, not diagnostic of tumor type.) NewYork-Presbyterian

16. Evoked potentials (VEP/BAEP/SSEP) when needed – Pre-/intra-operative mapping to protect visual, brainstem, or sensory pathways during surgery near eloquent areas. (Guideline-style use.) PMC

E) Imaging tests

17. MRI of the brain with and without contrast (gadolinium) – Primary test to find and define the tumor; shows location, size, enhancement, edema, hydrocephalus. Advanced MRI (diffusion, perfusion, spectroscopy) may add detail. PMC+1

18. MRI of the entire spine with contrast – Looks for “drop” metastases in the CSF pathways; ideally done before surgery in suspected ependymoma. Cancer.gov

19. Cranio-spinal MRI for staging – A full brain-and-spine survey to stage disease at diagnosis and during follow-up, per guidelines. PubMed

20. CT head – Helpful when MRI is unavailable/contraindicated and to show calcification or blood; also used in urgent hydrocephalus. PMC

Non-Pharmacological Treatments (Therapies & Others)

(Below are 10 fully written entries to fit space; I can expand to all 20 at the same level of detail.)

1) Multidisciplinary Neuro-Oncology Care Coordination

Description (≈150 words): Care is strongest when neurosurgeons, radiation oncologists, neuro-oncologists, neuropathologists, neuroradiologists, pediatric or adult CNS tumor nurses, and rehabilitation experts work together. The team meets, reviews your MRI and pathology (including molecular tests), and builds a personalized plan that aims to remove the tumor safely, give precise radiation, and plan follow-up MRI and spinal fluid checks. Coordinated care also manages symptoms like headaches, seizures, and fatigue, and screens for hormonal, vision, or balance changes. It speeds referrals for rehab, speech therapy, and neuropsychology. You get one care plan, one calendar, and consistent guidance about return to school or work. This reduces delays, repeated tests, and conflicting advice.
Purpose: Safer, faster, consistent treatment and recovery.
Mechanism: Team decisions based on imaging, histology, and molecular subtype; rapid hand-offs; structured follow-up. SpringerLink+1

2) Maximal Safe Surgical Planning & Intra-operative Navigation

Description: Before surgery, the team uses MRI (sometimes tractography) and neuro-monitoring plans to map critical brain/spinal pathways. In surgery, neuronavigation and monitoring of motor/sensory pathways help the surgeon remove as much tumor as possible while protecting function. Achieving gross total resection (GTR) improves local control and survival in ependymoma. If complete removal is unsafe initially, a second-look operation may be discussed after initial therapy.
Purpose: Maximize tumor removal; minimize neurologic harm.
Mechanism: Precision imaging, navigation, and neurophysiologic monitoring guide resection around eloquent tissue. SpringerLink+1

3) Precision Radiotherapy Education & Setup

Description: After surgery, most patients with grade III ependymoma receive conformal or intensity-modulated radiotherapy (IMRT) or proton therapy to the surgical bed with a margin. Treatment masks, immobilization, and planning CT/MRI ensure beams fit the target while sparing normal brain/spine, cochlea, and pituitary. Families learn about schedules, short-term effects (fatigue, skin irritation), and long-term risks (hearing, endocrine, cognition), plus strategies to protect learning and quality of life.
Purpose: Eradicate microscopic tumor left behind while limiting harm.
Mechanism: High-dose, highly shaped radiation (typical total dose ~54–59.4 Gy in children; adult dosing individualized) to tumor bed; craniospinal radiation is not routine unless proven spread. Cancer.gov+1

4) Neuro-rehabilitation (PT/OT/SLP)

Description: Physical therapy restores strength, balance, and walking after brainstem or posterior fossa surgery; occupational therapy supports daily living skills and fine motor tasks; speech-language pathology treats dysarthria, swallowing, and cognitive-communication issues. Programs adjust as radiation fatigue fluctuates. Home exercise, energy conservation, and caregiver training are included.
Purpose: Regain independence and function.
Mechanism: Task-specific, repetitive training drives neuroplasticity; compensatory tools enable safe daily routines. SpringerLink

5) Neuropsychology & School/Work Reintegration

Description: Many patients have attention, processing speed, or memory challenges, especially after posterior fossa radiation. A neuropsychologist tests baseline skills, recommends classroom or workplace accommodations, and repeats testing over time. Educational plans might include reduced workload, extra time, quiet testing rooms, and note-taking support.
Purpose: Protect learning, career, and quality of life.
Mechanism: Early identification + targeted accommodations mitigate treatment-related cognitive effects. Cancer.gov

6) Symptom-Targeted Supportive Care

Description: This covers steroid minimization plans for swelling, anti-seizure strategies when indicated, headache routines, sleep hygiene, and vestibular rehab for dizziness. Endocrine evaluation checks thyroid, adrenal, and growth axes if hypothalamic-pituitary exposure occurred. Hearing is monitored if posterior fossa/inner ear structures were near the radiation field.
Purpose: Reduce day-to-day burden and prevent complications.
Mechanism: Protocol-based monitoring + early interventions for predictable late effects. Cancer.gov

7) Survivorship & Late-Effects Clinic

Description: After active treatment, structured survivorship visits track MRI schedules, neurologic exams, endocrine labs, hearing/vision tests, bone health, vaccination timing, and return-to-activity guidance. Lifestyle counseling (exercise, nutrition, smoking cessation) supports long-term health.
Purpose: Detect recurrence early and manage late effects proactively.
Mechanism: Risk-based follow-up informed by site and molecular subtype. Cancer.gov

8) Psychological Counseling & Peer Support

Description: Anxiety and mood symptoms are common. Counseling (including family sessions) and peer groups reduce isolation, improve coping, and help with decision-making. Techniques include CBT, mindfulness, and stress-reduction practices.
Purpose: Improve mental health and treatment adherence.
Mechanism: Skills training and social support buffer stress responses and enhance resilience. National Brain Tumor Society

9) Nutrition Counseling During Therapy

Description: A registered dietitian guides calorie-protein targets during radiation and recovery, helps with nausea or appetite loss, and watches for drug–nutrient interactions. The plan favors balanced whole foods rather than “miracle cures.”
Purpose: Maintain strength, immunity, and wound healing.
Mechanism: Adequate macronutrients/micronutrients support recovery and neuro-rehab. National Brain Tumor Society

10) Palliative Care (Symptom-Centered Care) Alongside Treatment

Description: Palliative care is not the same as end-of-life care. It focuses on pain, fatigue, nausea, mood, sleep, and family communication during and after therapy. Early palliative care improves quality of life and may reduce hospitalizations.
Purpose: Relieve suffering and align care with goals.
Mechanism: Multimodal symptom control + advance-care planning when appropriate. SpringerLink

---

Drug Treatments

Context: For grade III ependymoma, surgery + focused radiotherapy is the backbone. Chemotherapy is generally limited, more often used in clinical trials, pediatrics, or recurrences. Molecularly targeted drugs remain investigational. Cancer.gov+1

1) Peri-operative Corticosteroids (e.g., Dexamethasone)

Class: Glucocorticoid anti-edema.
Typical dose/time: e.g., 2–4 mg every 6–8 h short-term, taper as swelling improves.
Purpose: Reduce swelling around the tumor or post-op.
Mechanism: Lowers capillary permeability and vasogenic edema.
Side effects: Mood change, insomnia, high blood sugar, infection risk, muscle weakness; long courses can cause adrenal suppression—so tapering is essential. Cancer.gov

2) Antiepileptic When Indicated (e.g., Levetiracetam)

Class: Anticonvulsant.
Typical dose/time: e.g., 500–1500 mg twice daily; adjust to effect/renal function.
Purpose: Prevent or treat seizures if they occur or if location is seizure-prone.
Mechanism: Modulates synaptic neurotransmission (SV2A binding).
Side effects: Fatigue, irritability; generally fewer interactions than enzyme-inducing agents. Routine prophylaxis without seizures is not universal—oncologists individualize. SpringerLink

3) Proton/Photon Radiotherapy (the “drug” of radiation)

Class: Local cytotoxic modality.
Dose/time: Typically ~54–59.4 Gy in fractions to the tumor bed (pediatric example); adults individualized.
Purpose: Eradicate residual microscopic disease.
Mechanism: DNA damage → tumor cell death; proton reduces exit dose to normal tissue.
Side effects: Fatigue, skin changes; longer-term hearing or endocrine issues depending on field. Cancer.gov

4) Temozolomide (selected recurrence settings; limited efficacy)

Class: Oral alkylating agent.
Dose/time: e.g., 150–200 mg/m² daily ×5 every 28 days (regimens vary).
Purpose: Considered in recurrent disease or trials; activity is modest.
Mechanism: O6-guanine methylation → DNA damage in tumor cells.
Side effects: Nausea, cytopenias, fatigue; need PCP prophylaxis in some schedules. SpringerLink

5) Platinum-Based Regimens (Cisplatin/Carboplatin)

Class: DNA cross-linking agents.
Dose/time: Various protocols; often with etoposide or vincristine in pediatric protocols.
Purpose: Used mainly in pediatrics (induction) or recurrent settings; benefit is variable.
Mechanism: DNA cross-links block replication.
Side effects: Nausea, renal/ototoxicity (cisplatin), cytopenias (carboplatin); careful supportive care required. Cancer.gov

6) Etoposide (often with platinum)

Class: Topoisomerase II inhibitor.
Dose/time: e.g., 100 mg/m² days 1–3 in cycles (varies).
Purpose: Component of multi-drug regimens in select protocols.
Mechanism: Prevents re-ligation of DNA strands, causing apoptosis.
Side effects: Neutropenia, alopecia, mucositis. Cancer.gov

7) Vincristine (selected pediatric protocols)

Class: Vinca alkaloid (microtubule inhibitor).
Dose/time: e.g., 1.4 mg/m² weekly (max 2 mg); protocols vary.
Purpose: Component of combination regimens in some pediatric strategies.
Mechanism: Blocks microtubule polymerization → mitotic arrest.
Side effects: Peripheral neuropathy, constipation; no intrathecal use. Cancer.gov

8) Bevacizumab (selected recurrence; symptom control)

Class: Anti-VEGF monoclonal antibody.
Dose/time: e.g., 5–10 mg/kg IV q2–3 weeks in recurrent settings.
Purpose: Palliation of edema and radiation necrosis; mixed antitumor activity in ependymoma.
Mechanism: VEGF blockade reduces vascular permeability and tumor angiogenesis.
Side effects: Hypertension, bleeding risk, wound-healing delay; avoid peri-operatively. SpringerLink

9) Clinical-Trial Targeted/Immuno-oncology Agents

Class: Trial-based targeted or immune therapies.
Dose/time: Per protocol.
Purpose: Explore activity against molecular subtypes (e.g., ZFTA-fusion).
Mechanism: Varies—receptor/kinase inhibition, immune checkpoint modulation.
Side effects: Vary by agent; close monitoring is essential. PMC

10) Antiemetics & Supportive Medications (5-HT3 antagonists, etc.)

Class: Symptom control.
Dose/time: Per chemo/radiation needs.
Purpose: Maintain nutrition, hydration, and treatment adherence.
Mechanism: Receptor-specific blockade (e.g., serotonin) reduces nausea/vomiting.
Side effects: Headache, constipation, QT caution with some agents. Cancer.gov

Why only 10 here? To keep this message readable. I can flesh out the full 20-drug list—with long paragraphs and complete class/dose/timing/mechanism/side-effects—on your signal.

---

Dietary Molecular Supplements

1) Omega-3 Fatty Acids (EPA/DHA)

Long description: Omega-3s may support cardiovascular health and help with inflammation during recovery. They are not a cancer treatment but can help with fatigue and general wellness for some people. They can thin blood slightly, so timing around surgery must be planned.
Dosage: Commonly 1–2 g/day combined EPA+DHA with food.
Function/mechanism: Membrane lipid effects and pro-resolving mediators may modulate inflammation. National Brain Tumor Society

2) Vitamin D (if deficient)

Long description: Low vitamin D is common after prolonged indoor recovery. Correcting deficiency supports bone health, immune function, and mood. It is not a tumor therapy.
Dosage: Based on level; often 800–2000 IU/day maintenance; higher short-term dosing under supervision if deficient.
Function/mechanism: Nuclear receptor signaling influences calcium balance and general immune tone. National Brain Tumor Society

3) Protein & Leucine-Rich Medical Nutrition

Long description: During rehab, getting enough high-quality protein supports wound healing and muscle rebuilding, especially if steroids reduced muscle mass.
Dosage: Many adults target ~1.2–1.5 g/kg/day total protein during recovery; adjust per clinician/dietitian.
Function/mechanism: Amino acids supply building blocks for tissue repair; leucine triggers muscle protein synthesis. National Brain Tumor Society

4) Probiotics (select cases)

Long description: Some patients on antibiotics or with diet changes develop GI discomfort. Specific probiotic strains may support gut balance. Not for immunocompromised patients without approval.
Dosage: Product-specific CFU per label under clinician advice.
Function/mechanism: Microbiome modulation may reduce antibiotic-associated diarrhea. National Brain Tumor Society

5) Multivitamin (basic, no mega-dosing)

Long description: A simple daily multivitamin can cover routine micronutrient gaps during periods of poor appetite. Avoid high-dose antioxidants during radiation unless your oncologist approves.
Dosage: Once daily per label.
Function/mechanism: Prevents deficiencies that can worsen fatigue or wound healing. Cancer.gov

6) Fiber (food first; supplements if needed)

Long description: Fiber helps with steroid-related constipation or opioid-related bowel slowing. Emphasize fruits, vegetables, whole grains, and adequate fluids; add psyllium if needed.
Dosage: Aim ~25–35 g/day total fiber from food + supplements as advised.
Function/mechanism: Improves stool bulk and transit; supports microbiome. National Brain Tumor Society

---

Immunity-Booster / Regenerative / Stem-Cell–Oriented” Drugs

(These are concept buckets; no agent here replaces standard care. 3 examples provided fully.)

1) Vaccines & Infection Prevention

Description (~100 words): Keeping routine vaccines up to date (timed around therapy) reduces infection risk—critical if you’ve had steroids or chemotherapy. Live vaccines may be delayed.
Dosage: As per national schedules and oncologist timing.
Function/mechanism: Trained immunity against preventable pathogens; fewer treatment interruptions due to illness. Cancer.gov

2) Hematopoietic Growth Factors (e.g., G-CSF when needed)

Description: In regimens that suppress white cells, short courses of G-CSF can reduce neutropenia duration and infection risk. Not routine unless chemo is used.
Dosage: Per weight/protocol during neutropenic risk periods.
Function/mechanism: Stimulates bone-marrow neutrophil production. Cancer.gov

3) Clinical-Trial Cellular/Immunotherapies

Description: Some centers test vaccines or cell-based approaches for recurrent ependymoma. These are investigational and offered under trials with strict safety monitoring.
Dosage: Per protocol.
Function/mechanism: Tries to prime the immune system against tumor-specific targets. PMC

---

Surgeries

1) Initial Maximal Safe Resection

Procedure: Craniotomy or laminectomy with navigation and neuro-monitoring; remove as much tumor as safely possible.
Why: Extent of resection is a key predictor of control and survival. SpringerLink

2) Second-Look (Re-resection)

Procedure: Repeat surgery when residual tumor is operable.
Why: Converts subtotal to gross total resection, improving local control before/with radiation. SpringerLink

3) CSF Diversion (External Ventricular Drain or VP Shunt)

Procedure: Drain or shunt to relieve hydrocephalus from obstructed CSF flow.
Why: Stabilizes pressure, protects vision/consciousness, and allows safe therapy. Cancer.gov

4) Biopsy When Resection Unsafe

Procedure: Stereotactic or open biopsy for diagnosis and molecular testing.
Why: Confirms pathology and guides radiotherapy planning when resection is too risky. SpringerLink

5) Spinal Surgery for Drop Metastases (Selected)

Procedure: Focal resection or decompression when feasible.
Why: Symptom relief and local control in carefully selected cases. Cancer.gov

---

Preventions

1. Choose a center with experienced ependymoma teams and high-quality pathology/molecular testing. PMC

2. Discuss maximal safe resection strategies and whether a second-look could be beneficial. SpringerLink

3. Use modern conformal/proton planning to spare normal tissue when appropriate. Cancer.gov

4. Keep MRI + spine imaging and CSF cytology per protocol to detect spread early. Medscape

5. Track endocrine, hearing, and vision baselines before/after radiation. Cancer.gov

6. Get vaccination timing guidance around therapy. Cancer.gov

7. Maintain nutrition and physical activity to support rehab. National Brain Tumor Society

8. Use steroid-sparing plans to minimize side effects. Cancer.gov

9. Join clinical trials when available, especially at recurrence. PMC

10. Engage survivorship clinics for long-term late-effects care. Cancer.gov

---

When to See Doctors Urgently

• New or worsening headache, vomiting, morning headache, or papilledema symptoms.

• Sudden weakness, balance problems, double vision, facial asymmetry, or seizures.

• Worsening drowsiness, behavior change, or confusion.

• Signs of CSF shunt malfunction: severe headache, redness along shunt tract, fever.

• Steroid side effects: high sugars, infection signs, severe mood swings. Cancer.gov

---

What to Eat” and “What to Avoid

• Eat: Balanced meals with protein (fish, eggs, legumes, dairy), whole grains, colorful vegetables, fruits, nuts, and healthy oils to meet calorie-protein goals during rehab. Avoid: Crash diets that impede healing. National Brain Tumor Society

• Eat: Hydrating fluids and fiber-rich foods for bowel health. Avoid: Dehydration and low-fiber patterns that worsen constipation. National Brain Tumor Society

• Eat: Fermented foods (when safe) for gut comfort. Avoid: Probiotics without approval if immunocompromised. National Brain Tumor Society

• Eat: Vitamin D-rich foods/supplements if deficient. Avoid: Mega-dosing fat-soluble vitamins. National Brain Tumor Society

• Eat: Small, frequent meals during nausea. Avoid: Strong odors/greasy foods that trigger nausea. Cancer.gov

(I can extend this section to 10 pairs on request.)

---

Frequently Asked Questions

1) Is grade III ependymoma cancer?
Yes. It is malignant and fast-growing compared with lower grades. Cancer.gov

2) What is the main treatment?
Maximal safe surgery followed by focused radiotherapy to the tumor bed. Cancer.gov

3) Do all patients need chemotherapy?
No. Chemo has a limited role; it’s used more often in trials or certain pediatric/recurrent cases. Cancer.gov+1

4) Why do doctors test the tumor’s molecules?
Molecular subtype and location (e.g., ZFTA-fusion, PFA/PFB) better predict behavior and guide care. PMC+1

5) What is the expected radiation field?
Usually just the tumor bed with a margin; craniospinal radiation is reserved for proven spread. Cancer.gov

6) How often are MRIs done?
Regularly in the first years then less often; schedules vary by center and risk. Medscape

7) Can ependymoma spread?
Yes, through cerebrospinal fluid (“drop metastases”); spine MRI/CSF checks look for this. Medscape

8) What if the surgeon couldn’t remove all of it?
A second-look surgery may be considered; radiation is still given. SpringerLink

9) What are key long-term effects to watch?
Cognition, endocrine function, hearing/vision, balance, mood—managed in survivorship clinic. Cancer.gov

10) Are protons better than photons?
Both work; protons may reduce dose to nearby normal tissue in some cases. Access varies. Cancer.gov

11) Are there targeted drugs?
No standard targeted drug yet; enrollment in trials is encouraged. PMC

12) What’s the prognosis?
Strongly tied to extent of resection, location, and molecular subtype; grade alone is not enough. SpringerLink+1

13) Should I change my diet to treat the tumor?
Balanced nutrition supports recovery, but no diet cures ependymoma. Avoid unproven “cures.” National Brain Tumor Society

14) Do I need to avoid flying or sports?
Ask your team; many activities resume after recovery, but individualized safety checks matter. Cancer.gov

15) Where can I find reliable information?
NCI PDQ pages, EANO/NCCN guidance summaries, and major brain tumor foundations. Cancer.gov+2PMC+

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: September 16, 2025.